Track topics on Twitter Track topics that are important to you
- Part 1: To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLTs) of cabazitaxel administered as a 1-hour infusion in combination with gemcitabine, every 3 weeks in patients with advanced solid malignancies.
- Part 2: To determine the antitumor activity of cabazitaxel in combination with gemcitabine, in an additional extended cohort of 15 patients with advanced solid malignancies treated with the defined MTD, as assessed by objective response rate (ORR) according to the revised guideline for Response Evaluation Criteria in Solid Tumours (RECIST 1.1 criteria).
- To assess the safety profile of the combination regimen of cabazitaxel with gemcitabine.
- To assess the pharmacokinetics (PK) of cabazitaxel, gemcitabine and its metabolite, and 2,2 difluoridine when given in combination.
- To determine Time to Progression (TTP), Objective Response Rate (ORR), and Duration of Response (DR), in the extended cohort of patients treated at the MTD in Part 2 of the study and the patients who received the MTD in Part 1 component.
- To assess the potential inhibitory effect of cabazitaxel on CYP3A4 using midazolam, a CYP3A4 probe since cabazitaxel inhibits CYP3A4 in vitro.
The study consists of a screening phase (maximum length of 21-day), a treatment phase with 21-day study treatment cycles. Cycle lengths may be extended up to maximum of 2 additional weeks in case of unresolved toxicity. Patients will be treated until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.There will be a 30-day follow-up visit after the last dose of study medication. Patients who discontinue study treatment prior to disease progression will continue to have tumor assessments every 6 weeks until disease progression or start of an other anticancer therapy.
The cut off date for the study is defined as follows: all patients will be followed up until disease progression, unacceptable toxicity, consent withdrawal or when the last patient had completed 26 weeks or 6 cycles on study treatment, whichever comes first. Patients may continue to be treated on study as long as they are benefiting from study treatment and have not met study withdrawal criteria. After withdrawal from study treatment, further treatment, if any, is at the discretion of the Investigator.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
cabazitaxel (XRP6258), gemcitabine, midazolam
Sanofi-Aventis Investigational Site Number 840002
Published on BioPortfolio: 2014-07-23T21:12:18-0400
Primary Objective: - To assess the potential effect on QTcF interval (QTc Fridericia) of cabazitaxel in cancer patients Secondary Objectives: - To assess the effe...
Primary Objectives: - To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic ...
The purpose of this study is to evaluate the safety and dosing of cabazitaxel with cisplatin given every 3 weeks in patients with advanced solid cancer. Other objectives of this study is ...
Primary Objective: To evaluate the safety of cabazitaxel (Jevtana) in patients with metastatic hormone refractory prostate cancer Secondary Objectives: 1. To describe the ...
Primary Objectives: - To determine the maximum tolerated dose, and dose limiting toxicities of cabazitaxel administered as a 1-hour infusion every 3 weeks in combination with ora...
Midazolam has been successfully used for sedation, which the tablets, injections and oral solutions were available in market. However, the oral bioavailability of midazolam is less due to the first ef...
Urachal neoplasms are uncommon and represent a minor portion of bladder tumors. According to the recently updated World Health Organization classification (2016), these tumors are classified as adenom...
To obtain routine clinical practice data on cabazitaxel usage patterns for patients with metastatic castration-resistant prostate cancer (mCRPC) and to describe physician-assessed cabazitaxel effectiv...
- Pleural pathology has been dominated by discussions relating to the diagnosis, prognosis, etiology, and management of malignant mesothelioma. However, there exists a diverse group of other neoplasms...
To evaluated the apoptosis in parotid glands of rats treated with Midazolam associated or not with Pilocarpine, Sixty Wistar rats were assigned to 6 groups: control group received saline solution for ...
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
Distinctive neoplastic disorders of histiocytes. Included are malignant neoplasms of MACROPHAGES and DENDRITIC CELLS.
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
Benign and malignant neoplasms that arise from one or more of the twelve cranial nerves.
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...